Agree with this strategy by management, they will need to raise fund for this in the next 6 months. Key catalyst are the clinical trial updates for VAXINIA, OASIS and Azer-Cel before then in the next 3-6 months.
PD1-Vaxx will be used to support a Phase 2, Investigator Sponsored Trial (IST) known as Neo-POLEM which will start in the first half of 2025. The trial is expected to recruit approximately 40 patients with colorectal cancer in Australia and the UK, whereby PD1- Vaxx will be administered before surgery (neoadjuvant). As previously stated, the B-cell immunotherapies have been deprioritized to focus on the azer-cel and Oncolytic Virus programs. Management continues to pursue out-licensing opportunities for its B-cell immunotherapies.
IMU Price at posting:
3.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)